Abstract |
Tibric acid [CP-18.524; 2-chloro-5-(3,5-dimethyl-piperidino-sulfonyl- benzoic acid], a new hypolipidemic drug was given to 20 patients with primary endogenous hyperlipoproteinemia of type II, III, IV and V Fredrickson in a daily dose of 1.5 g for 1 year. As compared to a 4-week placebo period, the treatment with tibric acid led to a significant decrease in plasma cholesterol in 6 type-II patients (p less than 0.02) and to a significant decrease in plasma cholesterol and triglycerides in 6 type-III patients (p less than 0.001 and p less than 0.001, resp.) and in 4 type-IV patients (p less than 0.001 and p less than 0.001, resp.). No significant effect of tibric acid on plasma lipids was noted in 4 type-V patients. Apart from a moderate nausea in two patients, no side effects occurred.
|
Authors | H J Lisch, S Sailer, H Braunsteiner |
Journal | Arzneimittel-Forschung
(Arzneimittelforschung)
Vol. 27
Issue 10
Pg. 2017-20
( 1977)
ISSN: 0004-4172 [Print] Germany |
Vernacular Title | Effekt von Tibrinsäure (CP-18.524) auf die Plasmalipide von Patienten mit primärer endogener Hyperlipoprotein amie. |
PMID | 579116
(Publication Type: Clinical Trial, Controlled Clinical Trial, English Abstract, Journal Article)
|
Chemical References |
- Hypolipidemic Agents
- Lipids
- Piperidines
- Triglycerides
- Cholesterol
|
Topics |
- Adult
- Aged
- Cholesterol
(blood)
- Drug Evaluation
- Humans
- Hyperlipidemias
(blood, drug therapy)
- Hypolipidemic Agents
(therapeutic use)
- Lipids
(blood)
- Middle Aged
- Piperidines
(pharmacology, therapeutic use)
- Triglycerides
(blood)
|